In 2016, an analysis of the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party for the effect of CD34-selection of AHSCT on the outcome of 138 patients with SSc showed that CD34-graft selection did not add any benefit on overall survival or incidence of disease progression [71]. This evidence concerns the gene CD34 and systemic sclerosis.